tradermen
Forumer storico
oltre agli anni bisesti..
..non é che che c'é qualcos'altro che si ripresenta dopo 4anni ?!?
NicOx SA - Google Finance
..
..
..
..
certo che ne abbiamo di vice presidenti..
a che serviranno tutti questi..??
Pharma e Biotech - Europa NicOx : Quelli che aspettano ,,,, ridendo !!!
- Creatore Discussione acqua+
- Data di Inizio
- Stato
certo che ne abbiamo di vice presidenti..
a che serviranno tutti questi..??
Netzach
Forumer storico
certo che ne abbiamo di vice presidenti..
A riempire i ptf loro e .... svuotare i nostri ...
DickSIM
Prima o poi....ci becco!
comunque sta cosa dei quattro decimali nella quotazione è veramente UNA BUFFONATA!
sarà uscita dalla mente bacata di qualche parruccone che nn ha mai un caxxo da fare........
: e per partorire queste PERLE si prenderà minimo 25.000€ al mese....... mavafffffffff.............. 
sarà uscita dalla mente bacata di qualche parruccone che nn ha mai un caxxo da fare........
: e per partorire queste PERLE si prenderà minimo 25.000€ al mese....... mavafffffffff.............. 
magolibero
..se la sà gira..
tradermen
Forumer storico
News AMF et nicox
DECLARANT :
Ennio ONGINI, Vice Président de la Recherche
INSTRUMENT FINANCIER : Actions
NATURE DE L’OPÉRATION : Souscription
DATE DE L’OPÉRATION : 23 décembre 2009
DATE DE RECEPTION DE LA DECLARATION : 29 décembre 2009
LIEU DE L’OPÉRATION : Euronext Paris
PRIX UNITAIRE : 3,49 €
MONTANT DE L’OPÉRATION : 16 193,60 €
DECLARANT :
Ennio ONGINI, Vice Président de la Recherche
INSTRUMENT FINANCIER : Actions
NATURE DE L’OPÉRATION : Souscription
DATE DE L’OPÉRATION : 23 décembre 2009
DATE DE RECEPTION DE LA DECLARATION : 29 décembre 2009
LIEU DE L’OPÉRATION : Euronext Paris
PRIX UNITAIRE : 3,49 €
MONTANT DE L’OPÉRATION : 16 193,60 €
magolibero
..se la sà gira..
altra conference per NicOx il 02/12/10
Pharma Market Research Conference - Pogram Agenda
Best Practice: How to Design and Execute Market Research for Senior Decision Makers
Too often extensive / exhaustive / expensive research is completed with little to no impact on final decision making considerations.
Find out what others have done to ensure their research is the center point of any important decision-making process and what you can learn from their experience.
Moderator:
- Thomas Han, Senior Director, Strategic Marketing Business Analysis, Biovail
Panelists:
- David Berman, Sr. Director, Global Customer Insights, Merck
- Grace Samoil Reynolds, Sr Director Global Strategic Analytics, Johnson & Johnson
- Sanjiv Sharma, Vice-President of Commercial Affairs, Nicox
- Stuart Greenberg, Deputy Director, Global Market Research, Bayer
- Glen Misek, Director, Marketing Analytics and Business Insights, Abbott (invited)
- Paul Snyderman, Chief Research Officer, Ipsos Health
Sanjiv Sharma -Vice-President of Commercial Affairs - Nicox
Sanjiv Sharma has successful experience both at National and Global levels in Pharmaceutical Marketing, Sales Management, Strategic Planning, Market Access, and Government Affairs. He has a sound knowledge of pharmaceutical markets and healthcare systems in both North American and Asia.
Currently, as a VP Commercial Affairs, He heads the commercial operations for NicOx SA and He is responsible for implementing a global commercial strategy for NicOx’ portfolio and defining and implementing the strategy for establishing sales and marketing operations in preparation for the launch of naproxcinod, the first compound in the CINOD class and the Company’s lead product for the treatment of the signs and symptoms of osteoarthritis.
Sanjiv is also heads NicOx’s US operations and is a member of the Company’s Executive Committee. Before joining NicOx, He was head of Strategic Marketing & Business Analysis (SMBA) function for Biovail Pharmaceutical Inc, USA. In this role, he was responsible for new product commercialization and strategic life cycle management across five therapeutic areas with a special focus on Wellbutrin XL and Ultram ER franchise: marketing of the current legacy product portfolio.
Before joining Biovail, he worked for Sanofi-Aventis and its predecessor companies for 15 years. During these 15 years, he experienced the success of several companies’ key brands through various commercial roles, e.g. Cardizem, Lovenox, Altace, Texotare, Amaryl, Lantus and Exubera.
In the Global Marketing role in USA, He led several global cross-functional teams, in a matrix organization involving R&D, business development, brand teams for USA, Japan and EU. Actively involved or led several strategic endeavors, e.g., Roadmap for Aventis Diabetes leadership; Non injectable insulins strategy: North American Leadership Strategy; Aventis first Global Dynamic Diabetes Market Model for strategic planning and forecasting multiple opportunities, and was also involved in several major Business Development deals and
partnerships.
At Aventis Canada, He was a member of the Management Committee (PMC) .Led three functional departments within commercial affairs and led or involved in five products launches.
For his contribution in building innovative healthcare solutions, he was awarded “ The Year 2000 Who’s Who in Healthcare” by Rogers Media, the largest healthcare publishing group in Canada. He holds MBA with Distinction from Richard Ivey School of Business, University of Western Ontario, Canada, and was designated as an Ivey Scholar for Scholastic Excellence.
Pharma Market Research Conference - Pogram Agenda
Best Practice: How to Design and Execute Market Research for Senior Decision Makers
Too often extensive / exhaustive / expensive research is completed with little to no impact on final decision making considerations.
Find out what others have done to ensure their research is the center point of any important decision-making process and what you can learn from their experience.
Moderator:
- Thomas Han, Senior Director, Strategic Marketing Business Analysis, Biovail
Panelists:
- David Berman, Sr. Director, Global Customer Insights, Merck
- Grace Samoil Reynolds, Sr Director Global Strategic Analytics, Johnson & Johnson
- Sanjiv Sharma, Vice-President of Commercial Affairs, Nicox
- Stuart Greenberg, Deputy Director, Global Market Research, Bayer
- Glen Misek, Director, Marketing Analytics and Business Insights, Abbott (invited)
- Paul Snyderman, Chief Research Officer, Ipsos Health
Sanjiv Sharma has successful experience both at National and Global levels in Pharmaceutical Marketing, Sales Management, Strategic Planning, Market Access, and Government Affairs. He has a sound knowledge of pharmaceutical markets and healthcare systems in both North American and Asia.
Currently, as a VP Commercial Affairs, He heads the commercial operations for NicOx SA and He is responsible for implementing a global commercial strategy for NicOx’ portfolio and defining and implementing the strategy for establishing sales and marketing operations in preparation for the launch of naproxcinod, the first compound in the CINOD class and the Company’s lead product for the treatment of the signs and symptoms of osteoarthritis.
Sanjiv is also heads NicOx’s US operations and is a member of the Company’s Executive Committee. Before joining NicOx, He was head of Strategic Marketing & Business Analysis (SMBA) function for Biovail Pharmaceutical Inc, USA. In this role, he was responsible for new product commercialization and strategic life cycle management across five therapeutic areas with a special focus on Wellbutrin XL and Ultram ER franchise: marketing of the current legacy product portfolio.
Before joining Biovail, he worked for Sanofi-Aventis and its predecessor companies for 15 years. During these 15 years, he experienced the success of several companies’ key brands through various commercial roles, e.g. Cardizem, Lovenox, Altace, Texotare, Amaryl, Lantus and Exubera.
In the Global Marketing role in USA, He led several global cross-functional teams, in a matrix organization involving R&D, business development, brand teams for USA, Japan and EU. Actively involved or led several strategic endeavors, e.g., Roadmap for Aventis Diabetes leadership; Non injectable insulins strategy: North American Leadership Strategy; Aventis first Global Dynamic Diabetes Market Model for strategic planning and forecasting multiple opportunities, and was also involved in several major Business Development deals and
partnerships.
At Aventis Canada, He was a member of the Management Committee (PMC) .Led three functional departments within commercial affairs and led or involved in five products launches.
For his contribution in building innovative healthcare solutions, he was awarded “ The Year 2000 Who’s Who in Healthcare” by Rogers Media, the largest healthcare publishing group in Canada. He holds MBA with Distinction from Richard Ivey School of Business, University of Western Ontario, Canada, and was designated as an Ivey Scholar for Scholastic Excellence.
Netzach
Forumer storico
comunque sta cosa dei quattro decimali nella quotazione è veramente UNA BUFFONATA!
sarà uscita dalla mente bacata di qualche parruccone che nn ha mai un caxxo da fare........
Specialmente perchè solo gli istituzionali possono fare ordini a 4 decimali ...
Il solito giochetto : il trading vero solo per loro, e la marmaglia per acquisti massivi in fase di picco o di pre-cerino ...
PIZZODIGINO
Pacifico
-----------------------------
Chissà se un giorno ci avvicineremo a certi prezzi da noi tutti sognati ?
doctor NO
NO nel DNA
Specialmente perchè solo gli istituzionali possono fare ordini a 4 decimali ...
Il solito giochetto : il trading vero solo per loro, e la marmaglia per acquisti massivi in fase di picco o di pre-cerino ...
Ecco vedi che adesso dopo qualche anno di esperienza capisci come funziona
il trading da marmaglia è esattamente cosi
a noi resta solo puntare ed aspettare un'eventuale jackpot- Stato
